Touchlight Showcases Cell-Free DNA Platform and Cost Advantages at ASGCT

A LinkedIn post from Touchlight highlights the company’s planned scientific contributions at the ASGCT meeting, focusing on cell‑free DNA technologies for cell and gene therapy. The post outlines an oral presentation on novel lipid‑based formulations for delivering single‑stranded mbDNA to improve homology‑directed repair knock‑in efficiency in primary human T cells.

The company’s LinkedIn post also points to three posters covering enzymatic circular DNA payloads, a comparative cost of goods analysis between dbDNA and plasmid DNA for AAV manufacturing, and cell‑free z‑dbDNA templates for high‑yield RNA with reduced dsRNA impurities. These topics suggest an emphasis on process economics and product quality, areas that may influence Touchlight’s competitive position in enabling gene therapy manufacturing.

For investors, the focus on cost of goods and improved delivery efficiency may indicate that Touchlight is positioning its platform as a potentially more scalable and economical alternative to traditional plasmid DNA. If these data are well received by industry stakeholders at ASGCT, the visibility could support future partnerships or licensing discussions, though commercial impact will depend on subsequent validation and adoption.

The LinkedIn post’s invitation to access posters via the company’s website suggests an effort to broaden engagement beyond conference attendees. This outreach may help deepen relationships with biopharma developers and could expand Touchlight’s business development pipeline over time, particularly in segments where manufacturing constraints and purity requirements are key decision drivers.